Mycobacterium mucogenicum: Difference between revisions
Jump to navigation
Jump to search
Shanshan Cen (talk | contribs) |
Shanshan Cen (talk | contribs) |
||
| Line 38: | Line 38: | ||
==Treatment== | ==Treatment== | ||
===Antimicrobial regimen=== | ===Antimicrobial regimen=== | ||
* susceptible agents <ref>{{Cite journal| doi = 10.1164/rccm.200604-571ST| issn = 1073-449X| volume = 175| issue = 4| pages = 367–416| last1 = Griffith| first1 = David E.| last2 = Aksamit| first2 = Timothy| last3 = Brown-Elliott| first3 = Barbara A.| last4 = Catanzaro| first4 = Antonino| last5 = Daley| first5 = Charles| last6 = Gordin| first6 = Fred| last7 = Holland| first7 = Steven M.| last8 = Horsburgh| first8 = Robert| last9 = Huitt| first9 = Gwen| last10 = Iademarco| first10 = Michael F.| last11 = Iseman| first11 = Michael| last12 = Olivier| first12 = Kenneth| last13 = Ruoss| first13 = Stephen| last14 = von Reyn| first14 = C. Fordham| last15 = Wallace| first15 = Richard J.| last16 = Winthrop| first16 = Kevin| last17 = ATS Mycobacterial Diseases Subcommittee| last18 = American Thoracic Society| last19 = Infectious Disease Society of America| title = An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases| journal = American Journal of Respiratory and Critical Care Medicine| date = 2007-02-15| pmid = 17277290}}</ref>: [[Aminoglycosides]], [[Cefoxitin]], [[Clarithromycin]], [[Minocycline]], [[Doxycycline]], [[Quinolones]], [[Trimethoprim/sulfamethoxazole]], and [[Imipenem]] | * susceptible agents <ref>{{Cite journal| doi = 10.1164/rccm.200604-571ST| issn = 1073-449X| volume = 175| issue = 4| pages = 367–416| last1 = Griffith| first1 = David E.| last2 = Aksamit| first2 = Timothy| last3 = Brown-Elliott| first3 = Barbara A.| last4 = Catanzaro| first4 = Antonino| last5 = Daley| first5 = Charles| last6 = Gordin| first6 = Fred| last7 = Holland| first7 = Steven M.| last8 = Horsburgh| first8 = Robert| last9 = Huitt| first9 = Gwen| last10 = Iademarco| first10 = Michael F.| last11 = Iseman| first11 = Michael| last12 = Olivier| first12 = Kenneth| last13 = Ruoss| first13 = Stephen| last14 = von Reyn| first14 = C. Fordham| last15 = Wallace| first15 = Richard J.| last16 = Winthrop| first16 = Kevin| last17 = ATS Mycobacterial Diseases Subcommittee| last18 = American Thoracic Society| last19 = Infectious Disease Society of America| title = An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases| journal = American Journal of Respiratory and Critical Care Medicine| date = 2007-02-15| pmid = 17277290}}</ref>: [[Aminoglycosides]], [[Cefoxitin]], [[Clarithromycin]], [[Minocycline]], [[Doxycycline]], [[Quinolones]],[[Trimethoprim/sulfamethoxazole]], and [[Imipenem]] | ||
==References== | ==References== | ||
Revision as of 15:04, 7 July 2015
| Mycobacterium mucogenicum | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scientific classification | ||||||||||||||
| ||||||||||||||
| Binomial name | ||||||||||||||
| Mycobacterium mucogenicum Springer et al. 1995, ATCC 49650 |
Mycobacterium mucogenicum
Etymology: mucogenicum, from the organism's highly mucoid appearance.
Description
Gram-positive, nonmotile, curved and acid-fast rods.
Colony characteristics
- Highly mucoid behavior of most strains on solid agar. Smooth and off-white on Middlebrook 7H10 agar
Physiology
- Rapid growth on Middlebrook 7H10 at 28°C to 37°C, but not at 42°C, within 2 - 4 days.
- Susceptible to amikacin, imipenem, cefoxitin, clarithromycin and ciprofloxacin.
- Resistant to isoniazid and rifampin.
Pathogenesis
- Posttraumatic skin infections,
- catheter sepsis and respiratory isolates without clinical significance except in immunocompromised hosts.
- Biosafety level 2
Type Strain
- First isolated in 1976 during an outbreak of peritonitis associated with automated peritoneal dialysis machines in the north-western United States.
- Strain ATCC 49650 = CCUG 47451 = CIP 105223 = DSM 44625 = JCM 13575.
Treatment
Antimicrobial regimen
- susceptible agents [1]: Aminoglycosides, Cefoxitin, Clarithromycin, Minocycline, Doxycycline, Quinolones,Trimethoprim/sulfamethoxazole, and Imipenem
References
- ↑ Griffith, David E.; Aksamit, Timothy; Brown-Elliott, Barbara A.; Catanzaro, Antonino; Daley, Charles; Gordin, Fred; Holland, Steven M.; Horsburgh, Robert; Huitt, Gwen; Iademarco, Michael F.; Iseman, Michael; Olivier, Kenneth; Ruoss, Stephen; von Reyn, C. Fordham; Wallace, Richard J.; Winthrop, Kevin; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America (2007-02-15). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". American Journal of Respiratory and Critical Care Medicine. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. ISSN 1073-449X. PMID 17277290.
- Springer et al. 1995. Phylogeny of the Mycobacterium chelonae-like organism based on partial sequencing of the 16S rRNA gene and proposal of Mycobacterium mucogenicum sp. nov. Int. J. Syst. Bacteriol., 45, 262-267.